{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-257374","form_type":"8-K","ticker":"ABPO","cik":"0001893219","company_name":"Abpro Holdings, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.277834+00:00","generated_at":"2026-05-30T01:09:45.827105+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Abpro Holdings completes SPAC merger; to trade on Nasdaq under 'ABP' starting Nov. 14","bullets":["Business combination between Abpro Corporation and Atlantic Coastal Acquisition Corp. II closed; approved by Atlantic Coastal stockholders on Nov. 7.","Common stock to trade on Nasdaq Global Market under 'ABP'; warrants on Nasdaq Capital Market under 'ABPWW' beginning Nov. 14, 2024.","Celltrion invested $5 million in a PIPE transaction and gained a board seat (Soo Young Lee).","Abpro focuses on next-gen antibody therapies for HER2+ cancers, Wet AMD/DME, and COVID-19 using DiversImmune platform.","Exclusive collaboration with Celltrion on ABP 102 (t-cell engager) for HER2+ breast, gastric, and pancreatic cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-257374","json":"https://secwatch.observer/filing/0001193125-24-257374.json","markdown":"https://secwatch.observer/filing/0001193125-24-257374.md","text":"https://secwatch.observer/filing/0001193125-24-257374.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1893219/000119312524257374/0001193125-24-257374-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1893219/000119312524257374/d873918d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:09:45.827105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}